Ayrancı Mustafa Kürşat, Küçükceran Kadir, Dündar Zerrin Defne
Necmettin Erbakan University Meram Faculty of Medicine Emergency Medicine Department Konya Turkey.
J Acute Med. 2021 Sep 1;11(3):90-98. doi: 10.6705/j.jacme.202109_11(3).0002.
Optimal management for trauma-induced coagulopathy (TIC) is a clinical conundrum. In conjunction with the transfusion of fresh-frozen plasma (FFP), additional administration of prothrombin complex concentrate (PCC) was proposed to bring about further coagulative benefit. However, investigations evaluating the efficacy as well as corresponding side effects were scarce and inconsistent. The aim of this study was to systematically review current literature and to perform a meta-analysis comparing FFP+PCC with FFP alone.
Web search followed by manual interrogation was performed to identify relevant literatures fulfilling the following criteria, subjects as TIC patients taking no baseline anticoagulants, without underlying coagulative disorders, and reported clinical consequences. Those comparing FFP alone with PCC alone were excluded. Comprehensive Meta-analysis software was utilized, and statistical results were delineated with odd ratio (OR), mean difference (MD), and 95% confidence interval (CI). I was calculated to determine heterogeneity. The primary endpoint was set as all-cause mortality, while the secondary endpoint consisted of international normalized ratio (INR) correction, transfusion of blood product, and thrombosis rate.
One hundred and sixty-four articles were included for preliminary evaluation, 3 of which were qualified for meta-analysis. A total of 840 subjects were pooled for assessment. Minimal heterogeneity was present in the comparisons (I < 25%). In the PCC + FFP cohort, reduced mortality rate was observed (OR: 0.631; 95% CI: 0.450-0.884, = 0.007) after pooling. Meanwhile, INR correction time was shorter under PCC + FFP (MD: -608.300 mins, < 0.001), whilst the rate showed no difference ( = 0.230). The PCC + FFP group is less likely to mandate transfusion of packed red blood cells ( < 0.001) and plasma ( < 0.001), but not platelet ( = 0.615). The incidence of deep vein thrombosis was comparable in the two groups ( = 0.460).
Compared with FFP only, PCC + FFP demonstrated better survival rate, favorable clinical recovery and no elevation of thromboembolism events after TIC.
创伤性凝血病(TIC)的最佳管理是一个临床难题。除输注新鲜冰冻血浆(FFP)外,有人建议额外给予凝血酶原复合物浓缩剂(PCC)以获得更大的凝血益处。然而,评估其疗效及相应副作用的研究很少且结果不一致。本研究旨在系统回顾当前文献,并对FFP+PCC与单纯FFP进行荟萃分析。
通过网络检索并辅以人工查询,以识别符合以下标准的相关文献:受试者为未服用基线抗凝剂、无潜在凝血障碍且报告了临床结果的TIC患者。排除那些单纯比较FFP与PCC的研究。使用综合荟萃分析软件,统计结果以比值比(OR)、平均差(MD)和95%置信区间(CI)表示。计算I²以确定异质性。主要终点设定为全因死亡率,次要终点包括国际标准化比值(INR)校正、血液制品输注和血栓形成率。
164篇文章纳入初步评估,其中3篇符合荟萃分析条件。共纳入840名受试者进行评估。各比较组间异质性极小(I²<25%)。汇总后发现,PCC+FFP组死亡率降低(OR:0.631;95%CI:0.450-0.884,P=0.007)。同时,PCC+FFP组INR校正时间更短(MD:-608.300分钟,P<0.001),而血栓形成率无差异(P=0.230)。PCC+FFP组输注悬浮红细胞(P<0.001)和血浆(P<0.001)的可能性较小,但输注血小板的可能性无差异(P=0.615)。两组深静脉血栓形成发生率相当(P=0.460)。
与单纯FFP相比,PCC+FFP在TIC后显示出更好的生存率、良好的临床恢复情况且血栓栓塞事件未增加。